Table 13.
Trials evaluating boron neutron capture therapy (BNCT) sorted by publication year
| Author | Year | Agent | Dose | n | Radiation regimen | Results |
|---|---|---|---|---|---|---|
| Coderre et al. [84] | 1997 | BPA | 130–250 mg/kg | 18 |
Maximum of 52.6 ± 4.9 Gy-Eq Minimum of 25.2 ± 4.2 Gy-Eq to the tumor |
Feasibility of the concept, no adverse events |
| Takagaki et al. [85] | 1997 | BSH | 20 mg/kg | 11 | N/A | 2‑year OSR: 50% |
| Chadha et al. [86] | 1998 | BPA | 250 mg/kg | 10 | Minimum of 20 to 32.3 Gy-Eq to the tumor | Median OS: 13.5 months |
|
Palmer et al. [83] |
2002 | BPA | 250–350 mg/kg | 22 | 8.8–14.2 Gy-Eq in 1–2 fractions |
Feasibility of the concept Mean tumor dose: 25.7 RBE Gy |
|
Capala et al. [87] |
2003 | BPA | 900 mg/kg | 17 |
Maximum of 8.0–15.5 Gy-Eq Average dose 3.3–6.1 Gy-Eq to the brain |
No severe acute toxicities |
| Diaz et al. [96] | 2003 | BPA | 250–330 mg/kg | 53 | Total of 8.9–15.9 Gy-Eq delivered in 1–3 fields | Feasibility of the concept |
|
Kageji et al. [88] |
2004 | BSH | N/A | 18 (16) | Maximum of 15–18 Gy-Eq to the tumor | Maximum vascular dose should be below 12 Gy |
|
Kiger et al. [89] |
2004 | BPA | 14 g/m2 | 6 | Maximum 7–7.7 Gy-Eq to the whole brain in two fractions | Median tumor dose: 57.8 RBE Gy |
|
Yamamoto et al. [90] |
2004 | BSH | 100 mg/kg | 9 (5) | Maximum vascular dose 10.8 Gy-Eq, 1 intraoperative fraction | Median OS: 23.2 months (GBM) |
| Miyatake et al. [91] | 2005 |
BSH & BPA |
5 g 250 mg/kg |
13 (10) | Maximum of 13 Gy-Eq to the normal brain | Mean volumetric reduction: 46.4% |
| Stenstam et al. [98] | 2007 | BPA | 900 mg/kg | 7 | Minimum of 36.9 Gy-Eq to the tumor (mean) | Postmortem whole brain slices showed local control in all cases |
| Henriksson et al. [100] | 2008 | BPA | 900 mg/kg | 30 | Average 3.2–6.1 Gy-Eq to normal brain, minimum of 15.4–54.3 Gy-Eq to the tumor |
Median TTP: 5.8 months Median OS: 14.2 months |
| Miyatake et al. [92] | 2009 |
BSH & BPA |
100 mg/kg 250–600 mg/kg |
22 (19) | Maximum of 13 Gy-Eq to the normal brain | Median OS: 9.6 months (rGBM) |
| Kawabata et al. [93] | 2009 |
BSH & BPA |
100 mg/kg 250–700 mg/kg |
21 | Maximum of 13–15 Gy-Eq to the normal brain, partially followed by 20–30 Gy photons (11) | Median OS: 15.6 months vs 23.5 months in combination with photons |
|
Aiyama et al. [95] |
2011 | BPA | 250 mg/kg | 2 (1) | Maximum of 12 Gy-Eq to the normal brain | No adverse events |
|
Kankaanranta et al. [97] |
2011 | BPA | 350–450 mg/kg | 22 (20) | Maximum average 6 Gy-Eq to normal brain, maximum peak of 8 Gy |
MDT: 400 mg/kg Median OS: 7 months (rGBM) |
n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)